Florian Krammer

Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice.

Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines.

Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis.

Alternative influenza vaccines made by insect cells.

Evaluation of the influenza A replicon for transient expression of recombinant proteins in mammalian cells.

Insect cells for antibody production: evaluation of an efficient alternative.

Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses.

Efficient transmission of pandemic H1N1 influenza viruses with high-level oseltamivir resistance.

Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes.

Attenuated influenza virus construct with enhanced hemagglutinin protein expression.

A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo.

Influenza virus infection in guinea pigs raised as livestock, Ecuador.

NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge.

Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice.

A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates.

1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans.

Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity.

H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice.

Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies.

B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination.

Purification of infective baculoviruses by monoliths.

Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs.

Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin.

Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.

H7N9 influenza viruses interact preferentially with α2,3-linked sialic acids and bind weakly to α2,6-linked sialic acids.

Influenza virus hemagglutinin stalk-based antibodies and vaccines.

The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines.

Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies.

One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge.

H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge.

Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.

Universal influenza virus vaccines: need for clinical trials.

Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.

Divergent H7 immunogens offer protection from H7N9 virus challenge.

An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans.

In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen.

Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin.

Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.

Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.

Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.

Animal models for influenza viruses: implications for universal vaccine development.

A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.

Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.

An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13.

Domestic pigs are susceptible to infection with influenza B viruses.

Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.

Advances in the development of influenza virus vaccines.

Emerging influenza viruses and the prospect of a universal influenza virus vaccine.

Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.

High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine.

Newcastle Disease Virus-Vectored H7 and H5 Live Vaccines Protect Chickens from Challenge with H7N9 or H5N1 Avian Influenza Viruses.

High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination.

Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses.

Hemagglutinin Receptor Binding of a Human Isolate of Influenza A(H10N8) Virus.

Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy.

The Quest for a Universal Flu Vaccine: Headless HA 2.0.

Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.

Ion efflux and influenza infection trigger NLRP3 inflammasome signaling in human dendritic cells.

Immune history profoundly affects broadly protective B cell responses to influenza.

Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.

Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets.

Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins.

Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans.

New England harbor seal H3N8 influenza virus retains avian-like receptor specificity.

Novel universal influenza virus vaccine approaches.

Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate.

Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.

Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.

Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection.

Obesity Outweighs Protection Conferred by Adjuvanted Influenza Vaccination.

Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact.

Canine H3N8 influenza vaccines partially protect mice against the canine H3N2 strain currently circulating in the United States.

Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus.

Cross-Reactive and Cross-Neutralizing Activity of Human Mumps Antibodies Against a Novel Mumps Virus From Bats.

Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination.

Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection.

Progesterone-Based Contraceptives Reduce Adaptive Immune Responses and Protection against Sequential Influenza A Virus Infections.

Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins.

A novel Zika virus mouse model reveals strain specific differences in virus pathogenesis and host inflammatory immune responses.

Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin.

Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.

Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity.

Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in Humans.

An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses.

Stopping emerging influenza viruses at their origin.

Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.

A cross-clade H5N1 influenza A virus neutralizing monoclonal antibody binds to a novel epitope within the vestigial esterase domain of hemagglutinin.

Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Toward a Universal Influenza Virus Vaccine: Potential Target Antigens and Critical Aspects for Vaccine Development.

Synthetic TLR4 and TLR7 ligands work additively via MyD88 to induce protective antiviral immunity in mice.

Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes.